Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Add as a preferred source on Google
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
